Abbreviations used in this paper: ACTH, adrenocorticotropic hormone; AngII, angiotensin II; AZF, adrenal zona fasciculata; BAPTA, 1,2 *bis*-(2-aminophenoxy)ethane-*N,N,N′,N″*-tetraacetic acid; NPS-ACTH, *O*-nitrophenyl, sulfenyl-adrenocorticotropin.

INTRODUCTION
============

Cortisol secretion from the adrenal zona fasciculata (AZF) occurs under the control of the pituitary peptide ACTH (adrenocorticotropic hormone) ([@bib50]). The molecular mechanisms that couple ACTH receptor activation to cortisol production are only partially understood. Early studies established that cAMP was the principal intracellular messenger for ACTH in AZF cells ([@bib23]; [@bib20]; [@bib47]; [@bib49]). ACTH stimulates cAMP synthesis in AZF cells, while cAMP mimics the steroidogenic actions of ACTH ([@bib22]; [@bib48]; [@bib50]; [@bib51]). Accordingly, bovine AZF cells express a high affinity, MC2-R melanocortin receptor coupled to adenylate cyclase through G~s~ ([@bib42]; [@bib44]).

Although cAMP appears to function as the primary intracellular messenger, Ca^2+^ may also act pivotally in ACTH-stimulated corticosteroid secretion. At concentrations that produce little or no measurable increase in cAMP synthesis, ACTH has been reported to increase intracellular Ca^2+^ concentration and stimulate cortisol secretion in bovine AZF cells ([@bib53]; [@bib34]). Similarly, the *O*-nitrophenyl, sulfenyl derivative of ACTH (NPS-ACTH) stimulates large increases in \[Ca^2+^\]~i~ and corticosteroid secretion at concentrations that trigger no measurable increases in cAMP synthesis in either rat or bovine AZF cells ([@bib40]; [@bib52]). Overall, these results suggest that cAMP and Ca^2+^ are dual messengers that are both required to mediate the full steroidogenic response to ACTH.

In this regard, a role for electrical events and depolarization-dependent Ca^2+^ entry in ACTH-stimulated cortisol secretion has been established ([@bib10]; [@bib38]). Specifically, bovine AZF cells express bTREK-1 leak-type K^+^ channels, which set the resting membrane potential ([@bib38]; [@bib14]). ACTH receptor activation is coupled to membrane depolarization and Ca^2+^ entry through the inhibition of bTREK-1 channels ([@bib10], [@bib11]; [@bib38]). Accordingly, organic Ca^2+^ antagonists inhibit T-type Ca^2+^ channels at concentrations that also inhibit ACTH-stimulated cortisol secretion ([@bib10]). The NPS-ACTH--stimulated increase in \[Ca^2+^\]~i~ in bovine AZF cells is also inhibited by organic Ca^2+^ antagonists at concentrations that inhibit T-type Ca^2+^ channels ([@bib52]). Thus, bTREK-1 appears to link ACTH receptor activation to cortisol secretion through depolarization-dependent Ca^2+^ entry.

The signaling mechanisms by which ACTH inhibits bTREK-1 channels are incompletely understood. They may involve multiple cAMP- and Ca^2+^-dependent pathways. Specifically, neuronal TREK-1 channels are inhibited by cAMP through PKA-dependent phosphorylation of a carboxyl-terminal serine that is also present in bTREK-1 channels ([@bib41]; [@bib26]). Although native bTREK-1 channels can also be inhibited by this mechanism, ACTH and cAMP inhibit bTREK-1 channels in AZF cells in the presence of any of several PKA antagonists ([@bib11]).

While all of the cAMP-dependent actions of ACTH in AZF cells were previously thought to be mediated by PKA, alternative signaling pathways for cAMP-mediated responses are likely present in these cells. Specifically, two cAMP-activated guanine nucleotide exchange factors, Epac1 and Epac2 (also known as cAMP-GEFI and cAMP-GEFII), have been identified and implicated in the regulation of proteins including ion channels ([@bib7]; [@bib33]; [@bib25]). While Epac1 is expressed in many tissues, Epac2 is robustly expressed in selected areas of the brain and the adrenal glands of rats and humans ([@bib33]). This raises the possibility that cAMP-dependent inhibition of bTREK-1 in the adrenal gland is mediated through separate PKA- and Epac2-dependent mechanisms.

In addition, studies with NPS-ACTH raise the possibility that ACTH might inhibit bTREK-1 by a Ca^2+^-dependent mechanism that is independent of both cAMP and PKA. In this regard, angiotensin II (AngII) which also stimulates cortisol secretion from bovine AZF cells, inhibits bTREK-1 in these cells by separate Ca^2+^- and ATP-dependent pathways ([@bib19]; [@bib16]; [@bib36]). Overall, our results and those of other investigators suggest that ACTH may regulate bTREK-1 channels by multiple cAMP- and Ca^2+^-dependent pathways.

In this regard, Epac1 and Epac2 possess cAMP binding domains that lack a specific glutamate residue present in the binding domain of PKA ([@bib8]). Using this information and rational drug design, novel cAMP analogues were developed that, at appropriate concentrations, selectively activate the Epac proteins ([@bib8]; [@bib6]). We have used one of these, 8-pCPT-2′-O-Me-cAMP, along with other agents involved in cAMP metabolism to further characterize the signaling pathways by which ACTH and cAMP inhibit bTREK-1 in bovine AZF cells. The goal of this study was to determine whether ACTH and cAMP could inhibit bTREK-1 by Epac2 as well as PKA-dependent pathways.

Some of these results have been reported in abstract form (H. Liu, J.A. Enyeart, and J.J. Enyeart. 2008. *Biophys*. *J*. 94:2181).

MATERIALS AND METHODS
=====================

Materials
---------

Tissue culture media, antibiotics, fibronectin, and FBS were obtained from Invitrogen. Coverslips were from Bellco. PBS, enzymes, 1,2 *bis*-(2-aminophenoxy)ethane-*N,N,N′,N″*-tetraacetic acid (BAPTA), MgATP, collagenase, DNase, H-89, nystatin, 8-pCPT-cAMP, and ACTH (1--24), AMP-PNP, and Rp-cAMPS were obtained from Sigma-Aldrich. PKI(6--22) amide and PKI(14--22)myristolated were purchased from EMD Biosciences, Inc. 8-pCPT-2′-O-Me-cAMP (Biolog \#C041) was purchased from Axxora, LLC. Human full-length cDNA for Epac2 (cAMP-GEFII, clone ID\# 4823935) was purchased from Open Biosystems. p3-CD8 clone was provided by B. Seed (Massachusetts General Hospital, Boston, MA). SignaTect cAMP-dependent protein kinase (PKA) assay system was from Promega. \[γ^32^P\] ATP was purchased from Perkin Elmer. NPS-ACTH was custom synthesized by Celtek Peptides.

Isolation and Culture of AZF Cells
----------------------------------

Bovine adrenal glands were obtained from steers (age 2--3 yr) at a local slaughterhouse. Isolated AZF cells were obtained and prepared as previously described ([@bib12]). After isolation, cells were either resuspended in DMEM/F12 (1:1) with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and the antioxidants α-tocopherol (1 μM), 20 nM selenite, and 100 μM ascorbic acid (DMEM/F12+) and plated for immediate use, or resuspended in FBS/5% DMSO, divided into 1 ml aliquots, and stored in liquid nitrogen for future use. To ensure cell attachment, dishes were treated with fibronectin (10 μg/ml) at 37°C for 30 min and then rinsed with warm, sterile PBS immediately before adding cells. For patch clamp experiments, cells were plated in DMEM/F12+ in 35-mm dishes containing 9-mm^2^ glass coverslips. Coverslips were treated with fibronectin (10 μg/ml) as described above. Cells were maintained at 37°C in a humidified atmosphere of 95% air--5% CO~2~.

Measurement of Epac2 mRNA
-------------------------

RNeasy columns (QIAGEN) that had been treated with RNase-free DNase (QIAGEN) to remove genomic contamination were used to extract total RNA from AZF cells that had been cultured for 48 h both with and without ACTH (2 nM) or confluent HEK293 cells. Poly(A)^+^ mRNA was extracted from total RNA using a Poly(A) Pure kit (Ambion). 7 μg of total or poly(A)^+^ mRNA were separated on a denaturing 8% formaldehyde, 1.0% agarose gel, and transferred to a nylon membrane (Gene Screen Plus, NEN). The RNA was fixed to the membrane by UV cross-linking using a Stratalinker (Stratagene). Northern blots were prehybridized in heat-sealable plastic bags for 2 h at 42°C in ULTRAhyb (Ambion) and then hybridized with a \[α ^32^P\]dCTP-labeled 700-bp *XHO1* fragment of h-Epac2 DNA overnight at 42°C in minimal volume of ULTRAhyb. After 18--24 h, membrane was washed twice at room temperature in 2× SSPE for 15 min, twice at 40°C in 1× SSPE, 1% SDS for 30 min, with a final wash at 40°C with 0.1× SSPE, 1% SDS for 15 min before exposing to a storage phosphor screen for 4--12 h. Northern autoradiogram was imaged using a Typhoon 9200 variable mode phosphorimager.

Patch Clamp Experiments
-----------------------

Patch clamp recordings of K^+^ channel currents were made in the whole cell and perforated patch configurations from bovine AZF cells. The standard external solution consisted of 140 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 2 mM MgCl~2~, 10 mM HEPES, and 5 mM glucose, with pH adjusted to 7.3 using NaOH. The standard pipette solution consisted of 120 mM KCl, 1 mM CaCl~2~, 2 mM MgCl~2~, 11 mM BAPTA, 10 mM HEPES, 5 mM ATP, and 200 μM GTP, with pH titrated to 6.8 using KOH. The buffering capacity of pipette solutions was varied by adding combinations of CaCl~2~ and BAPTA or EGTA using the Bound and Determined software program ([@bib4]). Low and high capacity Ca^2+^ buffering solutions contained 0.5 mM EGTA and 11 mM BAPTA, respectively. The low capacity Ca^2+^ buffering solution was nominally Ca^2+^ free. \[Ca^2+^\]~i~ was buffered to 22 nM in the high capacity buffering solution. The patch pipette solution was maintained at pH 6.8 to enhance the expression of bTREK-1. For perforated patch recordings, the pipette solution contained 130 mM KCl, 2 mM MgCl~2~, and 20 mM HEPES, with pH adjusted to 6.8 using KOH. The pipette tip was filled with this solution and backfilled with this same solution supplemented with 120 μg/ml nystatin. Nystatin stock solutions (30 mg/ml) were made fresh daily in DMSO. Perforated patch recordings were made as previously described ([@bib27]).

Recording Conditions and Electronics
------------------------------------

AZF cells were used for patch clamp experiments 2--12 h after plating. Typically, cells with diameters \<15 μm and capacitances of 10--15 pF were selected. Coverslips were transferred from 35-mm culture dishes to the recording chamber (volume: 1.5 ml) that was continuously perfused by gravity at a rate of 3--5 ml/min. For whole cell recordings, patch electrodes with resistances of 1.0--2.0 MΩ were fabricated from Corning 0010 glass (World Precision Instruments). These electrodes routinely yielded access resistances of 1.5--4.0 MΩ and voltage-clamp time constants of \<100 μs. K^+^ currents were recorded at room temperature (22--25°C) according to the procedure of [@bib21] using a List EPC-7 patch clamp amplifier.

Pulse generation and data acquisition were done using a personal computer and PCLAMP software with Digidata 1200 interface (Axon Instruments, Inc.). Currents were digitized at 2--10 kHz after filtering with an 8-pole Bessel filter (Frequency Devices). Linear leak and capacity currents were subtracted from current records using summed scaled hyperpolarizing steps of 1/2 to 1/4 pulse amplitude. Data were analyzed using CLAMPFIT 9.2 (Molecular Devices) and SigmaPlot (version 10.0) software. Drugs were applied by bath perfusion, controlled manually by a six-way rotary valve.

PKA Assay
---------

PKA activity was measured with a SignaTECT cAMP-dependent protein kinase assay kit (Promega). This kit uses PKA-dependent phosphorylation of biotinylated peptides as a measure of PKA activity. AZF cells were plated on 60-mm fibronectin-treated dishes in DMEM/F12+ at a density of ∼4 × 10^6^ cells/dish. After 24 h, the serum-supplemented media was removed and replaced with either control media (DMEM/F12+) or the same media containing myristolyated PKI(14--22) and H-89. At the end of the incubation period, cells were washed two times with ice-cold PBS and suspended in 500 μl of cold extraction buffer (25 mM Tris-HCl pH 7.4, 0.5 mM EGTA, 10 mM β-mercaptoethanol, 0.5 mM Pefabloc-SC \[Roche Applied Science\], and protease inhibitors with EDTA \[Complete Mini protease inhibitor cocktail tablet, 1 per 10 ml lysis solution, Roche Applied Science\]). Lysates were homogenized using a cold Dounce homogenizer then centrifuged for 5 min at 4°C at 14,000 *g*. 5-μl samples of lysate supernatant were assayed using the SignaTECT cAMP-dependent protein kinase assay system. Each experimental condition was assayed in quadruplicate.

Transient Transfection and Visual Identification of HEK293 Cells Expressing bTREK-1
-----------------------------------------------------------------------------------

For patch clamp recording of bTREK-1 currents, HEK293 cells were cotransfected with a mixture of pCR®3.1-Uni-bTrek-1 and an expression plasmid (p3-CD8) for the α subunit of the human CD8 lymphocyte surface antigen at a 5:1 ratio using Lipofectamine (Life Technologies). Cells were visualized 1--2 d post transfection after a 15-min incubation with anti-CD8 antibody-coated beads (Dynal Biotech Inc.) as previously described ([@bib30]).

RESULTS
=======

Bovine AZF cells express two types of K^+^ channels: a voltage-gated, rapidly inactivating Kv1.4 channel, and a two pore domain, four transmembrane-spanning segment (2P/4TMS) bTREK-1 background K^+^ channel ([@bib39]; [@bib38]; [@bib13]; [@bib14]). In whole cell patch clamp recordings, bTREK-1 amplitude typically increases with time to a steady-state maximum. The absence of time- and voltage-dependent inactivation allows bTREK-1 K^+^ currents to be isolated in whole cell recordings using either of two voltage clamp protocols. When voltage steps of several hundred milliseconds duration are applied from a holding potential of −80 mV, bTREK-1 K^+^ current can be measured near the end of a voltage step when the Kv1.4 K^+^ current has fully inactivated ([Fig. 1, A--C](#fig1){ref-type="fig"}, left traces). Alternatively, bTREK-1 current can be selectively activated by an identical voltage step applied immediately after a 10-s prepulse to −20 mV has fully inactivated Kv1.4 channels ([Fig. 1, A--C](#fig1){ref-type="fig"}, right traces).

![Effect of PKA inhibitors on bTREK-1 inhibition by ACTH. Whole cell K^+^ currents were recorded from AZF cells in response to voltage steps applied from −80 mV at 30-s intervals with or without depolarizing prepulses to −20 mV. Pipettes contained standard solution or the same solution supplemented with PKI(6--22) amide (2 or 4 μM) alone or in combination with H-89 (5 or 10 μM). After bTREK-1 reached a stable maximum, cells were superfused with ACTH (1--24) (200 pM). (A--C) K^+^ current traces recorded with (right traces) and without (left traces) depolarizing prepulses, and corresponding plot of bTREK-1 amplitudes with (open circles) and without (closed circles) depolarizing pulses. Numbers on traces correspond to those on plots. (D) Summary of experiments as in A--C. Bars indicate mean ± SEM of bTREK-1 inhibition by 20 or 200 pM ACTH with or without PKA inhibitors as indicated.](jgp1320279f01){#fig1}

In whole cell recordings from bovine AZF cells, we previously showed that ACTH inhibits bTREK-1 current by a mechanism that was insensitive to PKA antagonists H-89 and a synthetic inhibitory peptide PKI(5--24) when either was added to the recording pipette ([@bib11]). This result indicated that ACTH could inhibit bTREK-1 by a PKA-independent pathway. In the present study, we measured the inhibition of bTREK-1 with the addition of a second PKI inhibitory peptide, PKI(6--22) amide, to the pipette solution, either alone or in combination with H-89. PKI(6--22) amide is a synthetic peptide patterned after a portion of the naturally occurring PKA inhibitory peptide and inhibits PKA with a reported IC~50~ of 1.7 nM ([@bib18]). When added to cytoplasmic extracts from AZF cells, PKI(6--22) amide (4 μM) and H-89 (10 μM) completely inhibited PKA activated by maximally effective concentrations of cAMP (see [Fig. 7 C](#fig7){ref-type="fig"}).

In contrast, when applied directly to the cytoplasm of AZF cells through the patch electrode, these PKA inhibitors failed to alter the potency or effectiveness of ACTH as an inhibitor of bTREK-1. ACTH inhibits bTREK-1 with an IC~50~ of 4.1 pM ([@bib38]). With standard pipette solution, ACTH (200 pM) inhibited bTREK-1 almost completely (95.2 ± 2.4%, *n* = 4) ([Fig. 1, A and D](#fig1){ref-type="fig"}). The addition of PKI(6--22) amide (2 or 4 μM) to the pipette solution did not blunt ACTH-induced inhibition of bTREK-1 ([Fig. 1 D](#fig1){ref-type="fig"}). PKI(6--22) amide in combination with H-89 (5 or 10 μM) also failed to significantly reduce ACTH-mediated inhibition of bTREK-1 ([Fig. 1, B and D](#fig1){ref-type="fig"}). The PKA inhibitors were also ineffective at reducing bTREK-1 inhibition by ACTH at a concentration of 20 pM where \<2% of all receptors would be activated ([@bib5]; [@bib44]) ([Fig. 1, C and D](#fig1){ref-type="fig"}).

bTREK-1 Inhibition by ACTH and cAMP Is Voltage Independent
----------------------------------------------------------

These results provide further proof that ACTH inhibits bTREK-1 by a PKA-independent mechanism. In this regard, cAMP acting through PKA was reported to inhibit hippocampal TREK-1 channels by a mechanism that converted TREK-1 from a voltage-insensitive leak channel into a voltage-gated outward rectifier ([@bib2]). When phosphorylated by PKA, TREK-1 channel open probability was markedly reduced only at negative potentials.

To determine whether ACTH or cAMP converted native bTREK-1 channels into voltage-gated channels, we measured bTREK-1 inhibition by ACTH (200 pM) or the membrane-permeable cAMP analogue 8-pCPT-cAMP over a wide range of test potentials. When bTREK-1 was activated by voltage steps between −60 and +40 mV, ACTH selectively inhibited this current almost completely at every test potential ([Fig. 2 A](#fig2){ref-type="fig"}). Similarly, when bTREK-1 currents were measured in response to voltage ramps between −100 and +100 mV, ACTH totally inhibited this current, even at the most positive test potential ([Fig. 2 A](#fig2){ref-type="fig"}).

![bTREK-1 inhibition by ACTH and 8-pCPT-cAMP is voltage independent. bTREK-1 was permitted to grow to a stable maximum before whole cell K^+^ currents were activated in response to voltage steps or voltage ramps before and after superfusion of ACTH or 8-pCPT-cAMP. Voltage steps were applied at 30-s intervals in 10-mV increments from a holding potential of −80 mV to test potentials from −60 to +40 mV. Voltage ramps were applied at 100 mV/s to potentials between +100 and −100 mV from a holding potential of 0 mV. (A) Effect of ACTH: K^+^ currents were recorded in response to voltage steps or voltage ramps before and after steady-state block by ACTH (200 pM). Top: current traces in response to voltage steps before and after ACTH. Bottom left: bTREK-1 amplitudes plotted against test potential before (closed circles) and after (open circles) ACTH. Bottom right: bTREK-1 current traces in response to ramp voltages before and after ACTH. (B, left) bTREK-1 amplitudes plotted against test potential in control saline (closed circles) and after 8-pCPT-cAMP (open circles). (B, right) bTREK-1 current traces in response to ramp voltages before and after 8-pCPT-cAMP.](jgp1320279f02){#fig2}

In similar experiments, the membrane-permeable cAMP analogue 8-pCPT-cAMP (300 μM) inhibited bTREK-1 with equal effectiveness over the same range of test voltages ([Fig. 2 B](#fig2){ref-type="fig"}). These results indicate that neither ACTH nor cAMP inhibit bTREK-1 solely by converting it to a voltage-gated channel through PKA phosphorylation. Overall, these findings are consistent with the hypothesis that ACTH inhibits bTREK-1 through separate PKA-dependent and -independent mechanisms.

NPS-ACTH Inhibits bTREK-1 by a PKA- and Ca^2+^-independent Mechanism
--------------------------------------------------------------------

Although our results are consistent with a model wherein ACTH inhibits bTREK-1 through parallel cAMP-dependent paths, they do not exclude the possibility that inhibition could also occur through a separate Ca^2+^-dependent mechanism.

NPS-ACTH reportedly increases \[Ca^2+^\]~i~ in bovine AZF cells with little or no increase in cAMP synthesis ([@bib52]). This peptide was used to determine if ACTH could inhibit bTREK-1 by a Ca^2+^-dependent pathway that is independent of cAMP. In this regard, AngII inhibits bTREK-1 by parallel Ca^2+^- and ATP hydrolysis--dependent signaling pathways that can be activated separately using two different pipette solutions ([@bib16]; [@bib36]). The standard pipette solution containing 5 mM MgATP with Ca^2+^ strongly buffered by 11 mM BAPTA facilitates selective activation of an ATP hydrolysis-dependent pathway. The Ca^2+^-dependent pathway can be selectively activated with a pipette solution containing UTP instead of ATP, and 0.5 mM EGTA instead of 11 mM BAPTA ([@bib16]).

It was discovered that NPS-ACTH inhibited bTREK-1 only through an ATP hydrolysis--dependent pathway. With pipette solution designed to permit selective activation of a Ca^2+^-dependent pathway, NPS-ACTH (1 nM) failed to significantly inhibit bTREK-1. In contrast, AngII (10 nM) in these same experiments inhibited bTREK-1 by 72.1 ± 4.2% (*n* = 3) ([Fig. 3 A](#fig3){ref-type="fig"}). With pipette solution that allowed selective activation of the ATP-dependent pathway, NPS-ACTH reversibly and completely inhibited bTREK-1 with an IC~50~ of 20.0 pM ([Fig. 3, B and C](#fig3){ref-type="fig"}).

![Inhibition of bTREK-1 by NPS-ACTH is Ca^2+^ and PKA independent. The inhibition of bTREK-1 in bovine AZF cells by NPS-ACTH was measured in whole cell patch clamp recordings using pipette solutions that permitted or blocked activation of Ca^2+^, ATP, or PKA-dependent signaling. K^+^ currents were recorded at 30-s intervals in response to voltage steps to +20 mV from a holding potential of −80 mV. After currents reached a stable maximum, cells were superfused with NPS-ACTH. (A and B) Effect of NPS-ACTH on bTREK-1 through Ca^2+^- and ATP hydrolysis--dependent pathways. bTREK-1 current amplitudes with (open circles) and without (closed circles) depolarizing prepulses are plotted against time. Pipette solutions contained (A) 2 mM UTP, 0.5 mM EGTA, (B) 5 mM MgATP, 11 mM BAPTA. NPS-ACTH and AngII were superfused at indicated times. (C) Concentration dependence of bTREK-1 inhibition and PKA activation by NPS-ACTH were measured in AZF cells and cell, respectively. Data were fit with an equation of the form (dotted line) I/I~MAX~ = 1/\[1 + (X/IC~50~)^B^\], where X is the NPS-ACTH concentration, and B is the Hill coefficient. IC~50~ is the concentration that reduces bTREK-1 by 50%. Values are mean ± SEM of indicated number of determinations, (solid line) PKA activity = 1/\[1+(X/EC~50~)^B^\], where X is the NPS-ACTH concentration, and B is the Hill coefficient. EC~50~ is the concentration that produces 1/2 of the maximum response. (D) Effect of PKA inhibitors on NPS-ACTH inhibition of bTREK-1. bTREK-1 current amplitudes are plotted against time. Pipette solution contained PKI(6--22)amide (4 μM) and H-89 (10 μM).](jgp1320279f03){#fig3}

These results suggested that NPS-ACTH may inhibit bTREK-1 by the same pathways as ACTH, although less potently. In this regard, the activation of PKA by ACTH in AZF cells serves as a remarkably sensitive measure of cAMP synthesis. In bovine AZF cells, ACTH activates PKA with an EC~50~ of 1.4 pM ([@bib9]). We found that NPS-ACTH activated PKA in AZF cells, but much less potently, with an EC~50~ of 336 pM ([Fig. 3 C](#fig3){ref-type="fig"}). Although less potent than ACTH, NPS-ACTH was equally effective as a PKA activator at maximum concentrations (unpublished data).

These results show that NPS-ACTH increases cAMP synthesis in AZF cells to a level sufficient to activate PKA. However, they also indicate that bTREK-1 inhibition by NPS-ACTH occurs at concentrations that produce minimal activation of PKA. Accordingly, we found that bTREK-1 inhibition by NPS-ACTH was not affected by including PKA inhibitors in the patch pipette ([Fig. 3 D](#fig3){ref-type="fig"}). Overall, these experiments showed that NPS-ACTH increases cAMP synthesis in AZF cells, but can inhibit bTREK-1 by a PKA- and Ca^2+^-independent mechanism.

Forskolin Inhibits bTREK-1 by a PKA-independent Mechanism
---------------------------------------------------------

Although all of the actions of ACTH in the adrenal cortex may require the synthesis of cAMP, the failure of PKA inhibitors to suppress bTREK-1 inhibition by ACTH could be indicative of a cAMP-independent, rather than a PKA-independent, action of cAMP. The di-terpene forskolin directly activates adenylate cyclase, increasing intracellular cAMP ([@bib1]). If cAMP inhibits bTREK-1 in AZF cells solely through activation of PKA, then including PKA inhibitors in the recording pipette should block bTREK-1 inhibition by forskolin. Under control conditions, forskolin (2.5 μM) inhibited bTREK-1 current by 76.9 ± 9.3% (*n* = 4) ([Fig. 4 A](#fig4){ref-type="fig"}). The addition of PKI(6--22) amide and H-89 to the pipette solution, at concentrations that completely inhibited PKA, failed to significantly reduce bTREK-1 inhibition by forskolin ([Fig. 4, B and C](#fig4){ref-type="fig"}). These findings are consistent with the hypothesis that ACTH and cAMP inhibit bTREK-1 by the same PKA-independent mechanism.

![Effect of PKA inhibitors on bTREK-1 inhibition by forskolin. Whole cell K^+^ currents were recorded from AZF cells in response to voltage steps applied from −80 mV at 30-s intervals with or without 10-s depolarizing prepulses to −20 mV. Patch pipettes contained standard solution or the same solution supplemented with PKI(6--22) amide (4 μM) alone or in combination with H-89 (5 or 10 μM). After bTREK-1 current reached a stable maximum, cells were superfused with forskolin (2.5 μM). (A and B) K^+^ current traces recorded with (right traces) and without (left traces) prepulses, and corresponding plot of bTREK-1 amplitudes with (open circles) or without (closed circles) depolarizing pulses. Numbers on traces correspond to those on plots. (C) Summary of experiments as in A and B. Bars indicate mean ± SEM of bTREK-1 inhibition by forskolin (2.5 μM) with or without PKA inhibitors, as indicated.](jgp1320279f04){#fig4}

Effect of 8-pCPT-2′-O-Me-cAMP on PKA Activity and bTREK-1 Current in Perforated Patch Recordings
------------------------------------------------------------------------------------------------

8-pCPT-2′-O-Me-cAMP has been reported to be a relatively selective activator of Epac proteins. It binds to Epac1 with 100-fold higher affinity than the cyclic nucleotide binding domain of the PKA regulatory subunit ([@bib8]; [@bib6]). When applied to cells in culture at concentrations up to 100 μM, 8-pCPT-2′-O-Me-cAMP has been reported to activate Epac1, but not PKA ([@bib8]). However, in experiments on bovine AZF cells, we found that at concentrations \>30 μM, 8-pCPT-2′-O-Me-cAMP produced significant increases in PKA activity. When applied externally at 100 μM, this cAMP analogue increased PKA activity approximately threefold over the control value (unpublished data).

These PKA activity measurements demonstrated that 8-pCPT-2′-O-Me-cAMP could be used in bovine AZF cells as a selective Epac activator at concentrations up to 30 μM. To determine whether 8-pCPT-2′-O-Me-cAMP could inhibit bTREK-1 independently of PKA, AZF cells were superfused with this agent while recording bTREK-1 currents with the nystatin perforated patch technique ([@bib27]). By using this technique, we hoped to minimize cell dialysis allowing 8-pCPT-2′-O-Me-cAMP to reach a higher intracellular concentration. However, in these experiments, 8-pCPT-2′-O-Me-cAMP (30 μM) inhibited bTREK-1 by only 10.2 ± 6.4% (*n* = 5), while ACTH (200 pM) inhibited bTREK-1 under the same conditions by 83.8 ± 2.8% (*n* = 7) ([Fig. 5, A and C](#fig5){ref-type="fig"}).

![Effect of 8-pCPT-cAMP on bTREK-1 currents in perforated patch recordings. (A and B) Perforated patch recordings: whole cell K^+^ currents were recorded in the nystatin perforated patch configuration in response to voltage steps applied at 30-s intervals from a holding potential of −80 to +20 mV with (right traces) or without (left traces) depolarizing prepulses. After bTREK-1 reached a stable amplitude, cells were superfused with 8-pCPT-2′-O-Me-cAMP (designated EA for Epac activator) (30 μM), ACTH (200 pM), or 8-pCPT-cAMP (30 or 300 μM), as indicated. Numbers on current traces correspond to those on plot at right. (C) Summary of experiments as in A and B. Bars indicate mean ± SEM of indicated number of determinations.](jgp1320279f05){#fig5}

The ineffectiveness of 8-pCPT-2′-O-Me-cAMP in perforated patch recordings suggested that ACTH and cAMP do not inhibit bTREK-1 through activation of Epac2. However, the membrane-permeable cAMP analogue 8-pCPT-cAMP, which potently activates PKA and Epac2 ([@bib6]), also failed to inhibit bTREK-1 when applied at a concentration of 30 μM in perforated patch recordings ([Fig. 5, B and C](#fig5){ref-type="fig"}). In contrast, at 10-fold higher concentrations, 8-pCPT-cAMP inhibited bTREK-1 by 91.2 ± 6.7 (*n* = 3) ([Fig. 5, B and C](#fig5){ref-type="fig"}). These findings indicate that even in perforated patch recordings, cyclic nucleotides applied externally fail to reach intracellular concentrations that are comparable to those present in the bath solution.

Inhibition of bTREK-1 by Intracellular Application of 8-pCPT-2′-O-Me-cAMP
-------------------------------------------------------------------------

Because of the limited effectiveness of the cAMP analogues when applied extracellularly at low concentrations and the associated uncertainty of their intracellular concentrations, we measured the effects of 8-pCPT-2′-O-Me-cAMP on bTREK-1 K^+^ channel activity when it was applied directly to the cytoplasm through the pipette. When applied through the pipette at concentrations from 1 to 30 μM, 8-pCPT-2′-O-Me-cAMP potently and effectively suppressed the time-dependent growth of bTREK-1 with an IC~50~ of 0.63 μM ([Fig. 6, A--D](#fig6){ref-type="fig"}). Notably, at a concentration of 1 μM, 8-pCPT-2′-O-Me-cAMP reduced bTREK-1 current density by 63.7% from a control value of 45.2 ± 5.9 pA/pF (*n* = 15) to 16.4 ± 4.4 pA/pF (*n* = 6). Using this low concentration of 8-pCPT-2′-O-Me-cAMP in the pipette, bTREK-1 amplitude initially grew, but then declined to a steady-state value ([Fig. 6 B](#fig6){ref-type="fig"}). At higher concentrations, the initial increase in bTREK-1 amplitude was absent and inhibition of bTREK-1 activity was nearly complete ([Fig. 6, C and D](#fig6){ref-type="fig"}). The inhibition of bTREK-1 expression by 8-pCPT-2′-O-Me-cAMP was specific. This agent did not alter the expression of the voltage-gated Kv1.4 current in these cells ([Fig. 6 E](#fig6){ref-type="fig"}).

![Concentration-dependent inhibition of bTREK-1 by 8-pCPT-2′-O-Me-cAMP. K^+^ currents were recorded from AZF cells with standard pipette solution or the same solution supplemented with 8-pCPT-2′-O-Me-cAMP (EA) at concentrations from 1 to 30 μM. Currents were recorded in response to voltage steps to +20 mV applied at 30-s intervals from a holding potential of −80 mV with and without depolarizing prepulses. (A--C) Time-dependent increase in bTREK-1 and inhibition by 8-pCPT-2′-O-Me-cAMP (EA). Current traces recorded with (right) and without (left) depolarizing prepulses at indicated times. bTREK-1 amplitudes are plotted at right. Open circles indicate traces recorded with depolarizing prepulse. (D) Summary of experiments as in A--C. Bars indicate bTREK-1 current density in pA/pF expressed as the mean ± SEM of the indicated number of determinations. (E) Effect of 8-pCPT-2′-O-Me-cAMP (EA) on Kv1.4 current. Bars indicate Kv1.4 current density in pA/pF expressed as the mean ± SEM of the indicated number of determinations in control saline and in the presence of 8-pCPT-2′-O-Me-cAMP (30 μM) (EA).](jgp1320279f06){#fig6}

When applied intracellularly through the patch pipette, 8-pCPT-2′-O-Me-cAMP inhibited bTREK-1 at concentrations similar to those that activate Epac in vitro (EC~50~ = 2.2 μM). By comparison, 10--20-fold higher concentrations were required to activate PKA holoenzyme ([@bib8]). Accordingly, we found that 8-pCPT-2′-O-Me-cAMP activated PKA in AZF cell lystates only at concentrations significantly higher than those required to inhibit bTREK-1 current ([Fig. 7 C](#fig7){ref-type="fig"}).

![bTREK-1 inhibition by 8-pCPT-2′-O-Me-cAMP is independent of PKA. (A--C) Whole cell K^+^ currents were recorded in response to voltage steps applied at 30-s intervals from −80 to +20 mV with or without depolarizing prepulses. Pipettes contained standard solution or the same solution supplemented with 8-pCPT-2′-O-Me-cAMP (EA), either alone or in combination with PKA inhibitors H-89 (10 μM), PKI(6--22) amide (4 μM), and Rp-cAMPS (500 μM), as indicated. When pipettes contained PKA inhibitors H-89 and PKI(6--22), cells were also pretreated for 30 min with H-89 (10 μM) and myristolated PKI(14--22) peptide (4 μM) before initiating recording. (A) Plots of bTREK-1 amplitude against time with pipettes containing indicated solutions. (B) Summary of experiments as in A. Bars indicate bTREK-1 current density in pA/pF expressed as the mean ± SEM of the indicated number of determinations. (C) Effect of 8-pCPT-2′-O-Me-cAMP (EA) and PKA inhibitors on PKA activity in AZF cell lysates: PKA activity was determined in cell lysates after incubating AZF cells either without (untreated) or with PKA inhibitors for 30 min. PKA activity in lysates from untreated cells was measured after 5 min with no further addition (control) or after addition of cAMP (5 μM) or 8-pCPT-2′-O-Me-cAMP (1--30 μM) (EA). PKA activity in lysates from PKA inhibitor--treated cells was measured after 5 min incubation with cAMP (5 μM) or 8-pCPT-2′-O-Me-cAMP (1--30 μM) (EA) and the PKA inhibitors as indicated. PKA activity is expressed as % of that activatable by 5 μM cAMP in control lysates. (D) Effect of AMP-PNP on 8-pCPT-2′-O-Me-cAMP inhibition of bTREK-1 current. bTREK-1 current was measured at 30-s intervals using patch pipettes containing AMP-PNP (2 mM) in place of ATP, or this same solution plus 8-pCPT-2′-O-Me-cAMP (30 μM) (EA). Bars represent mean ± SEM of maximum current density for the indicated number of determinations.](jgp1320279f07){#fig7}

Inhibition of bTREK-1 by 8-pCPT-2′-O-Me-cAMP Is Independent of PKA
------------------------------------------------------------------

The suppression of bTREK-1 expression in AZF cells by 8-pCPT-2′-O-Me-cAMP at concentrations that induce little or no activation of PKA indicate that this enzyme does not mediate the inhibition. Accordingly, 8-pCPT-2′-O-Me-cAMP was effective in inhibiting bTREK-1 activity in the presence of PKA antagonists.

In the experiments illustrated in [Fig. 7 (A and B)](#fig7){ref-type="fig"}, AZF cells were preincubated for at least 30 min with the cell-permeable PKA inhibitor myristolyated PKI(14--22) amide (4 μM) and H-89 (5 or 10 μM) before recording K^+^ currents with pipettes containing PKI(6--22) amide (4 μM) and H-89 (5 or 10 μM) with no further addition or with 8-pCPT-2′-O-Me-cAMP at several concentrations. The PKA inhibitors failed to suppress bTREK-1 inhibition by 8-pCPT-2′-O-Me-cAMP at concentrations from 5 to 30 μM ([Fig. 7, A and B](#fig7){ref-type="fig"}). In contrast, when PKI(6--22) amide and H-89 were added to AZF cell cytoplasmic extracts, PKA activation by 8-pCPT-2′-O-Me-cAMP (1--30 μM) or cAMP (5 μM) was completely inhibited to levels below control values ([Fig. 7 C](#fig7){ref-type="fig"}). Overall, 8-pCPT-2′-O-Me-cAMP effectively suppressed bTREK-1 channel activity under conditions where PKA had been completely eliminated.

Adenosine-3′-5′-cyclic monophosphorothioate, Rp isomer (Rp-cAMPS) competitively inhibits cAMP activation of PKA, but not Epac, in living cells ([@bib25]; [@bib43]). The presence of 500 μM Rp-cAMPS in the pipette solution failed to blunt the complete inhibition of bTREK-1 by 8-pCPT-2′-O-Me-cAMP (30 μM), providing further evidence for an Epac2-dependent inhibition of bTREK-1 ([Fig. 7, A and D](#fig7){ref-type="fig"}).

Inhibition of bTREK-1 by 8-pCPT-2′-O-Me-cAMP Requires Hydrolyzable ATP
----------------------------------------------------------------------

The inhibition of bTREK-1 by ACTH and 8-pCPT-cAMP requires hydrolyzable ATP ([@bib11]). If 8-pCPT-2′-O-Me-cAMP--mediated inhibition of bTREK-1 also proceeds through an ATP hydrolysis-dependent mechanism, then substitution of the nonhydrolyzable ATP analogue AMP-PNP for ATP in the pipette solution should eliminate inhibition by the Epac2 activator. Accordingly, when pipette solutions contained 2 mM AMP-PNP in place of ATP, 8-pCPT-2′-O-Me-cAMP (30 μM) failed to suppress bTREK-1 expression in whole cell recordings ([Fig. 7 D](#fig7){ref-type="fig"}).

Inhibition of bTREK-1 in Twice Patched Cells by 8-pCPT-2′-O-Me-cAMP
-------------------------------------------------------------------

In whole cell recordings, intracellularly applied 8-pCPT-2′-O-Me-cAMP suppressed bTREK-1 expression, even when the AZF cell had been preincubated with PKA inhibitors, and the patch electrode contained PKA inhibitors. To further demonstrate that 8-pCPT-2′-O-Me-cAMP inhibited bTREK-1 under conditions where PKA activity had been totally blocked in advance, AZF cells were sequentially patched with a pipette containing the PKA antagonists, followed by one containing these antagonists as well as 8-pCPT-2′-O-Me-cAMP.

Control experiments showed that AZF cells could often be consecutively patched with two pipettes without compromising the recording of bTREK-1 currents. In the experiment illustrated in [Fig. 8 A](#fig8){ref-type="fig"}, the cell was consecutively patched by two pipettes containing standard pipette solution. bTREK-1 current amplitude remained relatively constant upon voltage clamping the cell with the second pipette. In contrast, when the second pipette contained 8-pCPT-2′-O-Me-cAMP (15 μM), bTREK-1 was rapidly inhibited ([Fig. 8 B](#fig8){ref-type="fig"}). Similar results were obtained in each of four experiments.

![Inhibition of bTREK-1 by 8-pCPT-2′-O-Me-cAMP in twice-patched cells. Whole cell K^+^ currents were recorded in response to voltage steps to +20 mV applied at 30-s intervals from −80 mV, with or without depolarizing prepulses. Cells were sequentially patched with two pipettes containing standard solution, or the same solution supplemented with PKI(6--22) amide (4 μM), H-89 (10 μM), or 8-pCPT-2′-O-Me-cAMP (EA) as indicated. When bTREK-1 reached a stable maximum, the first pipette was withdrawn and the cell patched again with the second pipette. (A--C) Current traces and corresponding plots of bTREK-1 amplitude against time for cells patch clamped with pipettes containing the additions indicated. Closed circles represent pipette \#1, closed triangles, pipette \#2. Numbers on traces at left correspond to those on plot at right. Break in graph denotes time required to change patch pipettes.](jgp1320279f08){#fig8}

Finally, when cells were first voltage clamped with pipettes containing PKI (4 μM) and H-89 (10 μM) to preinhibit PKA, subsequent voltage clamp of the cell with patch electrodes containing the PKA inhibitors as well as 8-pCPT-2′-O-Me-cAMP produced near complete inhibition of bTREK-1 ([Fig. 8 C](#fig8){ref-type="fig"}).

8-pCPT-2′-O-Me-cAMP Fails to Inhibit bTREK-1 when Epac2 Expression Is Suppressed by ACTH
----------------------------------------------------------------------------------------

In a previous study, we demonstrated that prolonged treatment of AZF cells with ACTH enhances the expression of bTREK-1 mRNA and K^+^ channels ([@bib15]). We now report that, under similar conditions, ACTH markedly suppresses the expression of Epac2 mRNA. In the experiment illustrated in [Fig. 9 A](#fig9){ref-type="fig"}, AZF cells were treated with ACTH (2 nM) for 48 h before isolating mRNA. Northern analysis showed that Epac2-specific mRNA was markedly reduced, compared with its time-matched control.

![Effect of suppression of Epac2 expression on bTREK-1 inhibition by 8-pCPT-2′-O-Me-cAMP and 8-br-cAMP. (A) Northern blot analysis of ACTH inhibition of Epac2 mRNA expression. AZF cells were cultured either without (control) or with ACTH (2nM). mRNA was isolated after 48 h and analyzed as described in Materials and methods. (B) 8-pCPT-2′-O-Me-cAMP and bTREK-1 expression in ACTH-treated cells. AZF cells were exposed to ACTH (10 nM) for 72--96 h before patch clamping with pipettes containing PKI amide (6--22) (4 μM) and H89 (10 μM) (control), this same solution supplemented with 8-pCPT-2′-O-Me-cAMP (5 μM) (EA), or a solution containing 8-br-cAMP (15 μM). bTREK-1 current amplitudes are plotted against time. Bar graphs: summary of bTREK-1 maximum current densities. Values are mean ± SEM of indicated number of determinations. (C and D) Effect of ACTH treatment on bTREK-1 inhibition by 8-pCPT-2′-O-Me-cAMP in twice-patched cells. AZF cells were cultured in serum-supplemented media with (C) or without (D) 10 nM ACTH for 72--96 h before sequentially recording K^+^ currents with pipettes containing PKI amide (6--22) (4 μM) plus H89 (10 μM) and then these two agents plus 8-pCPT-2′-O-Me-cAMP (EA) (5 μM). K^+^ current traces recorded with (right traces) and without (left traces) depolarizing prepulses. Numbers on traces correspond to those on plots of bTREK-1 amplitude at right.](jgp1320279f09){#fig9}

When AZF cells were exposed to ACTH (10 nM) for 72 or 96 h before recording K^+^ currents, 8-pCPT-2′-O-Me-cAMP failed to inhibit bTREK-1 expression. In the experiments illustrated in [Fig. 9 B, K](#fig9){ref-type="fig"}^+^ currents were recorded from ACTH-treated cells with pipettes containing either standard solution plus PKA inhibitors, or the same solution supplemented with 8-pCPT-2′-O-Me-cAMP (5 μM). The maximum bTREK-1 current densities were nearly identical in the absence or presence of the Epac activator. In contrast, when K^+^ currents were recorded from ACTH-treated cells using pipettes containing 8-br-cAMP, which activates PKA as well as Epac2, bTREK-1 was nearly completely inhibited ([Fig. 9 B](#fig9){ref-type="fig"}).

In other experiments, AZF cells were treated for 72--96 h with ACTH (10 nM) before patch clamping them with pipettes containing PKA inhibitors followed by PKA inhibitors plus 8-pCPT-2′-O-Me-cAMP (5 μM). Under these conditions, 8-pCPT-2′-O-Me-cAMP (5 μM) failed to produce any inhibition of bTREK-1 current in each of four cells ([Fig. 9 C](#fig9){ref-type="fig"}). In fact, maximum bTREK-1 density was slightly increased from 26.1 ± 3.0 to 29.6 ± 7.9 pA/pF in the presence of the Epac activator. In contrast, when the experiment was repeated with cells that had not been pretreated with ACTH, 8-pCPT-2′-O-Me-cAMP inhibited bTREK-1 by 88.1 ± 3.1% (*n* = 4) ([Fig. 9 D](#fig9){ref-type="fig"}).

8-pCPT-2′-O-Me-cAMP Does Not Inhibit bTREK-1 Activity in Transfected HEK293 Cells
---------------------------------------------------------------------------------

Epac2 is robustly expressed in a limited number of tissues, including the adrenal glands of rats and humans ([@bib33]). However, the distribution of Epac2 expression within the adrenal has not been determined. Specifically, it hasn\'t been shown that Epac2 is expressed in adrenal cortical cells, rather than neural crest--derived adrenal chromaffin cells. In Northern blots of mRNA from bovine AZF cells, Epac2 was readily detected. By comparison, little or no Epac2 mRNA could be detected in HEK293 cells ([Fig. 10 D](#fig10){ref-type="fig"}). Experiments were done to determine whether 8-pCPT-2′-O-Me-cAMP could inhibit the activity of cloned bTREK-1 channels expressed in HEK293 cells where Epac2 is poorly expressed. In contrast to its effect in bovine AZF cells, the presence of 8-pCPT-2′-O-Me-cAMP in the pipette solution at 5 or 15 μM failed to alter the functional expression of bTREK-1 in transfected HEK293 cells ([Fig. 10, A and C](#fig10){ref-type="fig"}).

![6-Bnz-cAMP but not 8-pCPT-2′-O-Me-cAMP inhibits bTREK-1 channels expressed in HEK293 cells. Whole cell K^+^ currents were recorded from HEK293 cells that had been transiently transfected with pCR3.1 uni-bTREK-1 cDNA. K^+^ currents were activated by voltage steps to +20 mV, applied at 30-s intervals from a holding potential of −80 mV. Patch pipettes contained control saline or this same solution supplemented with 8-pCPT-2′-O-Me-cAMP (5 or 15 μM) (EA) or 6-Bnz-cAMP (15 μM). (A and B) Effect of 8-pCPT-2′-O-Me-cAMP (EA) and 6-Bnz-cAMP on bTREK-1 current. bTREK-1 current traces and associated time-dependent plots of current amplitudes. Numbers on traces correspond to those on plots at right. (C) Summary of experiments as shown in A and B. Bars indicate maximum bTREK-1 current density expressed as pA/pF. Values are mean ± SEM for indicated number of determinations. (D) Northern blot analysis of Epac2 in bovine AZF and HEK293 cells. Lanes contained 7 μg of poly(A)^+^ RNA from the indicated cells. Hybridization with hEpac2 probe was performed as described in Materials and methods.](jgp1320279f10){#fig10}

Although Epac2 may be absent from HEK293 cells, these cells do express functional PKA ([@bib46]). N6-benzoyl-cAMP (6-Bnz-cAMP) is a cAMP analogue that selectively activates PKA over Epac ([@bib6]). When 6-Bnz-cAMP (15 μM) was included in the pipette solution, the activity of transfected bTREK-1 K^+^ channels in HEK293 cells was markedly suppressed from a control value of 141.2 ± 25.8 pA/pF (*n* = 19) to 34.5 ± 6.4 pA/pF (*n* = 9) ([Fig. 10, B and D](#fig10){ref-type="fig"}). These results show that 8-pCPT-2′-O-Me-cAMP fails to inhibit bTREK-1 activity in cells that poorly express Epac2, while these same channels are inhibited in response to specific activation of PKA.

DISCUSSION
==========

The major findings of this study are that ACTH, NPS-ACTH, and cAMP inhibit bTREK-1 K^+^ channels in bovine AZF cells by multiple cAMP-dependent signaling pathways that likely involve the activation of both PKA and Epac2. bTREK-1 is among the first K^+^ channels identified thus far that is inhibited by parallel cAMP-dependent pathways. ATP-sensitive K^+^ channels of pancreatic β cells are also inhibited by cAMP through separate PKA- and Epac-dependent mechanisms ([@bib35]; [@bib32]). The convergent inhibition of bTREK-1 K^+^ channels by these two cAMP-dependent mechanisms provides for efficient fail-safe depolarization of AZF cells by ACTH.

PKA-independent Inhibition of bTREK-1 by ACTH and Forskolin
-----------------------------------------------------------

Experiments in which PKI(6--22) amide and H-89 failed to blunt bTREK-1 inhibition by ACTH or forskolin provide convincing evidence that inhibition of this channel by cAMP can occur through a PKA-independent mechanism. PKI(6--22) amide was used at concentrations ∼1,000--2,000 times the reported IC~50~ of 1.7 nM ([@bib18]). H-89, which competes with ATP for its binding site on PKA, was used at 100--200 times its reported IC~50~ of \<50 nM ([@bib24]). When applied together to AZF cell cytoplasmic extracts, these agents eliminated the activation of PKA by 8-pCPT-2′-O-Me-cAMP or cAMP. When applied together to the cytoplasm through the pipette solution, these agents should have completely blocked PKA activation by ACTH and forskolin, yet bTREK-1 inhibition was not affected.

The voltage-independent inhibition of bTREK-1 by ACTH and 8-pCPT-cAMP in the presence of PKA antagonists provided additional evidence that this response was not mediated through PKA. Previous studies showed that inhibition of neuronal TREK-1 channels by PKA-dependent phosphorylation occurred through a rightward shift in the voltage-dependent activation of these channels ([@bib2]; [@bib37]). Consequently, open probability was not reduced at positive test voltages. In AZF cells, bTREK-1 was effectively inhibited by ACTH and 8-pCPT-cAMP regardless of test potential, suggesting the involvement of a separate PKA-independent mechanism.

Ca^2+^- and PKA-independent Inhibition of bTREK-1 by NPS-ACTH
-------------------------------------------------------------

NPS-ACTH reversibly inhibited bTREK-1 current with an IC~50~ of 20 pM. Although this peptide was reported to trigger step-like and repetitive spike-like increases in \[Ca^2+^\]~i~ in bovine AZF cells ([@bib52]), it failed to inhibit bTREK-1 through a Ca^2+^-dependent pathway similar to that activated by AngII. In this regard, AngII-stimulated increases in \[Ca^2+^\]~i~ are mediated mainly by Ca^2+^ released from intracellular sites, while ACTH-mediated increases in \[Ca^2+^\]~i~ occur in response to Ca^2+^ influx through voltage-gated Ca^2+^ channels ([@bib52]; [@bib28]). In whole-cell patch clamp experiments where cells are voltage clamped at −80 mV, ACTH-stimulated influx through voltage-gated channels would be eliminated, preempting a Ca^2+^-dependent inhibition of bTREK-1. Under physiological conditions, Ca^2+^ entry through voltage-gated channels could contribute to ACTH-stimulated bTREK-1 inhibition and membrane depolarization.

NPS-ACTH did increase the concentration of cAMP in AZF cells to a level sufficient to activate PKA. However, similar to ACTH, the inhibition of bTREK-1 by NPS-ACTH appeared not to be mediated by PKA. First, NPS-ACTH inhibited bTREK-1 half-maximally at a concentration 16-fold lower than that required for half-maximal activation of PKA. Second, TREK-1 inhibition by NPS-ACTH was insensitive to PKA inhibitors. Overall, these results are consistent with a mechanism where, similar to ACTH, NPS-ACTH can inhibit bTREK-1 by a PKA-independent action of cAMP.

Inhibition of bTREK-1 by 8-pCPT-2′-O-Me-cAMP
--------------------------------------------

8-pCPT-2′-O-Me-cAMP potently and effectively inhibited bTREK-1 activity when applied intracellularly through the patch pipette in whole cell recordings. Several lines of evidence strongly indicate that this inhibition was mediated through Epac2. First, bTREK-1 expression was inhibited half-maximally with an IC~50~ of \<1 μM. This result is in excellent agreement with that reported for the potency of this agent in activating Epac1 and Epac2, where binding affinities and EC~50~s of 1--5 μM have been reported ([@bib8]; [@bib3]; [@bib45]). In contrast, 8-pCPT-2′-O-Me-cAMP activates PKA only at 10--20-fold higher concentrations, and is far less effective than cAMP in this respect ([@bib8]; [@bib3]).

Further, we showed that 8-pCPT-2′-O-Me-cAMP inhibited bTREK-1 completely at concentrations that produced little or no measurable increase in PKA activity in AZF cells. This agent also effectively inhibited bTREK-1 activity in cells where PKA had been inhibited by preincubating cells with PKA inhibitors and with these inhibitors included in the patch pipette at concentrations 100--1,000 times their reported EC~50~s. Third, 8-pCPT-2′-O-Me-cAMP inhibited bTREK-1 in twice-patched cells where PKA was first preinhibited by direct application of the two PKA inhibitors to the cytoplasm through the patch pipette. Finally, 8-pCPT-2′-O-Me-cAMP was ineffective at inhibiting bTREK-1 channels when Epac2 expression had been suppressed by prolonged exposure of AZF cells to ACTH, or in HEK293 cells that express little or no Epac2. In contrast, cAMP derivatives that activate PKA retained their effectiveness in these two systems.

It isn\'t known whether cAMP might also inhibit bTREK-1 in other cells through PKA- and Epac2-dependent signaling pathways. Since the expression of Epac2 is limited, other cells expressing both Epac2 and bTREK-1 have not yet been identified. It is possible that TREK-1 inhibition through Epac2 could occur in selected CNS neurons that express both of these proteins.

Signaling Mechanism for bTREK-1 Inhibition by 8-pCPT-2′-O-Me-cAMP
-----------------------------------------------------------------

The mechanism by which 8-pCPT-2′-O-Me-cAMP inhibits bTREK-1 K^+^ channels after activation of Epac2 is unknown. This Epac-selective cAMP analogue inhibits K~ATP~ K^+^ channels of pancreatic β cells and cell lines through an Epac2-dependent mechanism, wherein activated Epac2 interacts with the sulfonylurea receptor 1, a subunit of this inwardly rectifying K^+^ channel to reduce channel activity ([@bib31]). Further, it has recently been shown that Epac-selective cAMP activators function by sensitizing K~ATP~ K^+^ channels to inhibition by ATP, shifting the IC~50~ 20-fold ([@bib32]). bTREK-1 inhibition by this Epac-selective cyclic nucleotide occurs through a different mechanism, since inhibition is blocked when AMP-PNP replaces ATP in the pipette solution, indicating a requirement for ATP hydrolysis. Specific protein kinases activated by Epac2 have not been identified.

The failure of membrane-permeable 8′-substituted cAMP derivatives, including 8-pCPT-cAMP and 8-pCPT-2′-O-Me-cAMP to inhibit bTREK-1 when superfused externally at low concentrations in perforated patch recordings was unexpected. In perforated patch recording, whole cell dialysis is presumably limited when compared with standard whole cell recording. In standard whole cell recording, we previously found that 8-pCPT-cAMP inhibited bTREK-1 channels with an IC~50~ of 167 μM, a concentration much higher than that required to activate PKA in intact AZF cells ([@bib11]). Similar high concentrations of 8-pCPT-cAMP were also required to inhibit bTREK-1 in perforated patch recordings.

It seems likely that the reduced potency of cyclic nucleotides applied externally in perforated patch recordings stems from limited transport across the cell membrane. Their potency as bTREK-1 inhibitors increased markedly when they were directly applied to the cytoplasm through the patch pipette. Similar results have been seen in a study of the inhibition of K~ATP~ K^+^ channels by Epac-selective cAMP analogues in pancreatic β cells ([@bib31]).

Overall, the selectivity of 8-pCPT-2′-O-Me-cAMP as an Epac-specific activator may have been overstated in the initial studies of this and similar compounds ([@bib8]; [@bib6]; [@bib45]). It is clear that when applied externally to intact cells at concentrations \>50 μM, these agents produce significant activation of PKA and possibly other cAMP-activated proteins. Results obtained from experiments where these agents were used at concentrations of 100 μM or more in the absence of PKA inhibitors should be interpreted with caution.

Although we have found that bovine AZF cells express Epac2 and that an Epac-selective cAMP analogue inhibits bTREK-1 at low concentrations under conditions where PKA is inhibited, and fails to inhibit bTREK-1 in cells when Epac2 expression has been suppressed, the possibility remains that 8-pCPT-2′-O-Me-cAMP inhibits bTREK-1 through a cAMP-binding protein different than PKA or Epac2. PKA- and Epac-independent actions of cAMP have been observed in neurons and endocrine cells ([@bib29]; [@bib17]).

Our results demonstrate that ACTH inhibits bTREK-1 K^+^ channels in bovine AZF cells through activation of multiple cAMP-dependent signaling pathways. The convergent inhibition of bTREK-1 through separate PKA- and Epac2-dependent signaling pathways provides an efficient, reliable mechanism for membrane depolarization and Ca^2+^ entry.

The inhibition of bTREK-1 by parallel cAMP-dependent pathways resembles that for AngII inhibition of these same channels by separate Ca^2+^- and ATP hydrolysis--dependent pathways ([@bib16]; [@bib36]). In both instances, nature has developed fail-safe mechanisms for corticosteroid secretion in response to stress by activation of multiple convergent signaling pathways leading to membrane depolarization.
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